title: Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study.
abstract: OBJECTIVE
  The aim of this study was to investigate serious clinical outcomes associated with atrial fibrillation (AF) and the effects of routine blood pressure lowering on such outcomes in the presence or absence of AF, among individuals with type 2 diabetes.
  
  
  RESULTS
  About 11 140 patients with type 2 diabetes (7.6% of whom had AF at baseline) were randomized to a fixed combination of perindopril and indapamide or placebo in the Action in Diabetes and Vascular Disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) study. We compared total mortality and cardiovascular disease outcomes and effects of randomized treatment for 4.3 years on such outcomes between patients with and without AF at baseline. After multiple adjustments, AF was associated with a 61% (95% confidence interval 31-96, P < 0.0001) greater risk of all-cause mortality and comparable higher risks of cardiovascular death, stroke, and heart failure (all P < 0.001). Routine treatment with a fixed combination of perindopril and indapamide produced similar relative, but greater absolute, risk reductions for all-cause and cardiovascular mortalities in patients with AF, compared with those without AF. The number of patients needed to be treated with perindopril-indapamide for 5 years to prevent one cardiovascular death was 42 for patients with AF and 120 for patients without AF at baseline.
  
  
  CONCLUSIONS
  Atrial fibrillation is relatively common in type 2 diabetes and is associated with substantially increased risks of death and cardiovascular events in patients with type 2 diabetes. This arrhythmia identifies individuals who are likely to obtain greater absolute benefits from blood pressure-lowering treatment. Atrial fibrillation in diabetic patients should be regarded as a marker of particularly adverse outcome and prompt aggressive management of all risk factors.
authors.affiliation: The George Institute for International Health, University of Sydney, Level 10, King George V Building, Royal Prince Alfred Hospital, PO Box M201, Missenden Road, Camperdown, Sydney, NSW 2050, Australia.
authors.forename: Xin
authors.initials: X
authors.lastname: Du
authors.forename: Toshiharu
authors.initials: T
authors.lastname: Ninomiya
authors.forename: Bastiaan
authors.initials: B
authors.lastname: de Galan
authors.forename: Edward
authors.initials: E
authors.lastname: Abadir
authors.forename: John
authors.initials: J
authors.lastname: Chalmers
authors.forename: Avinesh
authors.initials: A
authors.lastname: Pillai
authors.forename: Mark
authors.initials: M
authors.lastname: Woodward
authors.forename: Mark
authors.initials: M
authors.lastname: Cooper
authors.forename: Stephen
authors.initials: S
authors.lastname: Harrap
authors.forename: Pavel
authors.initials: P
authors.lastname: Hamet
authors.forename: Neil
authors.initials: N
authors.lastname: Poulter
authors.forename: Gregory Y H
authors.initials: GY
authors.lastname: Lip
authors.forename: Anushka
authors.initials: A
authors.lastname: Patel
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D001786:Blood Glucose / Q000187:drug effects; D016001:Confidence Intervals; D003925:Diabetic Angiopathies / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007190:Indapamide / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D020913:Perindopril / Q000627:therapeutic use; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D001786:Blood Glucose; D007190:Indapamide; D020913:Perindopril